Sam68 promotes hepatic gluconeogenesis via CRTC2.
Aijun QiaoJunlan ZhouShiyue XuWenxia MaChan BoribounTeayoun KimBaolong YanJianxin DengLiu YangEric ZhangYuhua SongYongchao C MaStéphane RichardChunxiang ZhangHongyu QiuKirk M HabeggerJianyi Jay ZhangGangjian QinPublished in: Nature communications (2021)
Hepatic gluconeogenesis is essential for glucose homeostasis and also a therapeutic target for type 2 diabetes, but its mechanism is incompletely understood. Here, we report that Sam68, an RNA-binding adaptor protein and Src kinase substrate, is a novel regulator of hepatic gluconeogenesis. Both global and hepatic deletions of Sam68 significantly reduce blood glucose levels and the glucagon-induced expression of gluconeogenic genes. Protein, but not mRNA, levels of CRTC2, a crucial transcriptional regulator of gluconeogenesis, are >50% lower in Sam68-deficient hepatocytes than in wild-type hepatocytes. Sam68 interacts with CRTC2 and reduces CRTC2 ubiquitination. However, truncated mutants of Sam68 that lack the C- (Sam68ΔC) or N-terminal (Sam68ΔN) domains fails to bind CRTC2 or to stabilize CRTC2 protein, respectively, and transgenic Sam68ΔN mice recapitulate the blood-glucose and gluconeogenesis profile of Sam68-deficient mice. Hepatic Sam68 expression is also upregulated in patients with diabetes and in two diabetic mouse models, while hepatocyte-specific Sam68 deficiencies alleviate diabetic hyperglycemia and improves insulin sensitivity in mice. Thus, our results identify a role for Sam68 in hepatic gluconeogenesis, and Sam68 may represent a therapeutic target for diabetes.
Keyphrases
- blood glucose
- type diabetes
- binding protein
- glycemic control
- wild type
- poor prognosis
- cardiovascular disease
- transcription factor
- gene expression
- liver injury
- adipose tissue
- oxidative stress
- drug induced
- protein protein
- tyrosine kinase
- insulin resistance
- weight loss
- skeletal muscle
- amino acid
- nucleic acid
- protein kinase
- dna binding